{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T05:50:44Z","timestamp":1777701044369,"version":"3.51.4"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.bcp.2026.117867","type":"journal-article","created":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T16:17:44Z","timestamp":1772641064000},"page":"117867","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Nebivolol-induced bi-directional modulation of intracellular kinases contributes to the inhibition of triple-negative breast cancer"],"prefix":"10.1016","volume":"248","author":[{"given":"Huiwen","family":"Guan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunjun","family":"Ge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qianqian","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiaying","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang-Kun","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guosheng","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"19","key":"10.1016\/j.bcp.2026.117867_b0005","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1200\/JCO.2010.33.5422","article-title":"Beta blockers and breast cancer mortality: a population- based study","volume":"29","author":"Barron","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"19","key":"10.1016\/j.bcp.2026.117867_b0010","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1200\/JCO.2010.33.4441","article-title":"Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer","volume":"29","author":"Melhem-Bertrandt","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"16","key":"10.1016\/j.bcp.2026.117867_b0015","doi-asserted-by":"crossref","first-page":"4651","DOI":"10.1158\/1078-0432.CCR-17-0152","article-title":"Perioperative COX-2 and \u03b2-adrenergic blockade improves metastatic biomarkers in breast cancer patients in a phase-II randomized trial","volume":"23","author":"Shaashua","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"18","key":"10.1016\/j.bcp.2026.117867_b0020","doi-asserted-by":"crossref","first-page":"7042","DOI":"10.1158\/0008-5472.CAN-10-0522","article-title":"The sympathetic nervous system induces a metastatic switch in primary breast cancer","volume":"70","author":"Sloan","year":"2010","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.bcp.2026.117867_b0025","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1172\/JCI121685","article-title":"Stress-induced epinephrine enhances lactate dehydrogenase A and promotes breast cancer stem-like cells","volume":"129","author":"Cui","year":"2019","journal-title":"J. Clin. Invest."},{"issue":"6","key":"10.1016\/j.bcp.2026.117867_b0030","doi-asserted-by":"crossref","first-page":"963","DOI":"10.4149\/neo_2019_190110N34","article-title":"Evidence of beta-blockers drug repurposing for the treatment of triple negative breast cancer: a systematic review","volume":"66","author":"Spini","year":"2019","journal-title":"Neoplasma"},{"issue":"1","key":"10.1016\/j.bcp.2026.117867_b0035","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41413-021-00137-1","article-title":"Sympathetic activity in breast cancer and metastasis: partners in crime","volume":"9","author":"Conceicao","year":"2021","journal-title":"Bone Res."},{"issue":"3","key":"10.1016\/j.bcp.2026.117867_b0040","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.7150\/thno.81403","article-title":"Exploring neurotransmitters and their receptors for breast cancer prevention and treatment","volume":"13","author":"Li","year":"2023","journal-title":"Theranostics"},{"issue":"13","key":"10.1016\/j.bcp.2026.117867_b0045","doi-asserted-by":"crossref","DOI":"10.1096\/fj.202400725RR","article-title":"The multifaceted role of beta-blockers in overcoming cancer progression and drug resistance: Extending beyond cardiovascular disorders","volume":"38","author":"Cavalu","year":"2024","journal-title":"FASEB J."},{"issue":"3","key":"10.1016\/j.bcp.2026.117867_b0050","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1001\/jama.2018.19323","article-title":"Breast cancer treatment: a review","volume":"321","author":"Waks","year":"2019","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.bcp.2026.117867_b0055","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41571-021-00565-2","article-title":"Treatment landscape of triple-negative breast cancer - expanded options, evolving needs","volume":"19","author":"Bianchini","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.bcp.2026.117867_b0060","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1038\/s41416-022-01891-7","article-title":"Beta-blockers and breast cancer survival by molecular subtypes: a population-based cohort study and meta-analysis","volume":"127","author":"Lofling","year":"2022","journal-title":"Br. J. Cancer"},{"issue":"2","key":"10.1016\/j.bcp.2026.117867_b0065","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1111\/j.1476-5381.2011.01791.x","article-title":"Involvement of \u03b12- and \u03b22-adrenoceptors on breast cancer cell proliferation and tumour growth regulation","volume":"166","author":"P\u00e9rez Pi\u00f1ero","year":"2012","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bcp.2026.117867_b0070","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.bbi.2016.06.011","article-title":"Beta2-Adrenoceptors on tumor cells play a critical role in stress-enhanced metastasis in a mouse model of breast cancer","volume":"57","author":"Chang","year":"2016","journal-title":"Brain Behav. Immun."},{"issue":"14","key":"10.1016\/j.bcp.2026.117867_b0075","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2304897121","article-title":"The \u03b22-adrenergic receptor associates with CXCR4 multimers in human cancer cells","volume":"121","author":"Liang","year":"2024","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"1","key":"10.1016\/j.bcp.2026.117867_b0080","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s13058-015-0655-3","article-title":"Beta2-adrenoceptor signaling regulates invadopodia formation to enhance tumor cell invasion","volume":"17","author":"Creed","year":"2015","journal-title":"Breast Cancer Res."},{"issue":"3","key":"10.1016\/j.bcp.2026.117867_b0085","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1096\/fj.15-277798","article-title":"The beta2-adrenoceptor activates a positive cAMP-calcium feedforward loop to drive breast cancer cell invasion","volume":"30","author":"Pon","year":"2016","journal-title":"FASEB J."},{"issue":"8","key":"10.1016\/j.bcp.2026.117867_b0090","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1038\/s41593-019-0430-3","article-title":"Genetic manipulation of autonomic nerve fiber innervation and activity and its effect on breast cancer progression","volume":"22","author":"Kamiya","year":"2019","journal-title":"Nat. Neurosci."},{"issue":"6","key":"10.1016\/j.bcp.2026.117867_b0095","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s00280-023-04586-9","article-title":"The Beta2-adrenergic agonist salbutamol synergizes with paclitaxel on cell proliferation and tumor growth in triple negative breast cancer models","volume":"92","author":"Jablo\u00f1ski","year":"2023","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"10","key":"10.1016\/j.bcp.2026.117867_b0100","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1161\/01.RES.0000102042.83024.CA","article-title":"What is the role of beta-adrenergic signaling in heart failure?","volume":"93","author":"Lohse","year":"2003","journal-title":"Circ. Res."},{"issue":"1","key":"10.1016\/j.bcp.2026.117867_b0105","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1002\/jcb.27451","article-title":"MAPK\/ERK pathway inhibition is a promising treatment target for adrenocortical tumors","volume":"120","author":"Pereira","year":"2019","journal-title":"J. Cell. Biochem."},{"issue":"1","key":"10.1016\/j.bcp.2026.117867_b0110","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/s41392-021-00828-5","article-title":"Targeting PI3K\/Akt signal transduction for cancer therapy","volume":"6","author":"He","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"issue":"5","key":"10.1016\/j.bcp.2026.117867_b0115","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1111\/j.1476-5381.2009.00602.x","article-title":"Ligand-directed signalling at beta-adrenoceptors","volume":"159","author":"Evans","year":"2010","journal-title":"Br. J. Pharmacol."},{"issue":"3","key":"10.1016\/j.bcp.2026.117867_b0120","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1210\/en.2018-00843","article-title":"PI3K\u03b2\u2014A versatile transducer for GPCR, RTK, and small GTPase signaling","volume":"160","author":"Bresnick","year":"2019","journal-title":"Endocrinology"},{"issue":"6","key":"10.1016\/j.bcp.2026.117867_b0125","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1002\/med.21574","article-title":"JNK signaling in cancer cell survival","volume":"39","author":"Wu","year":"2019","journal-title":"Med. Res. Rev."},{"issue":"5","key":"10.1016\/j.bcp.2026.117867_b0130","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/s41580-020-00322-w","article-title":"Diversity and versatility of p38 kinase signalling in health and disease","volume":"22","author":"Canovas","year":"2021","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"2","key":"10.1016\/j.bcp.2026.117867_b0135","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s00432-023-05599-w","article-title":"Propranolol inhibits EMT and metastasis in breast cancer through miR-499-5p-mediated Sox6","volume":"150","author":"Zheng","year":"2024","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.bcp.2026.117867_b0140","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.abb.2014.05.030","article-title":"Quercetin-3-O-glucuronide inhibits noradrenaline-promoted invasion of MDA-MB-231 human breast cancer cells by blocking beta(2)-adrenergic signaling","volume":"557","author":"Yamazaki","year":"2014","journal-title":"Arch. Biochem. Biophys."},{"issue":"4","key":"10.1016\/j.bcp.2026.117867_b0145","first-page":"998","article-title":"Carvedilol suppresses migration and invasion of malignant breast cells by inactivating Src involving cAMP\/PKA and PKC\u03b4 signaling pathway","volume":"10","author":"Dezong","year":"2014","journal-title":"J. Cancer Res. Ther."},{"key":"10.1016\/j.bcp.2026.117867_b0150","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ejca.2021.01.029","article-title":"Carvedilol blocks neural regulation of breast cancer progression in vivo and is associated with reduced breast cancer mortality in patients","volume":"147","author":"Gillis","year":"2021","journal-title":"Eur. J. Cancer"},{"issue":"1","key":"10.1016\/j.bcp.2026.117867_b0155","doi-asserted-by":"crossref","first-page":"3606","DOI":"10.1038\/s41467-020-17384-1","article-title":"Coordinate beta-adrenergic inhibition of mitochondrial activity and angiogenesis arrest tumor growth","volume":"11","author":"Nuevo-Tapioles","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bcp.2026.117867_b0160","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.1049640","article-title":"Screening of GPCR drugs for repurposing in breast cancer","volume":"13","author":"Abdulkareem","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"6","key":"10.1016\/j.bcp.2026.117867_b0165","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1097\/CAD.0000000000001597","article-title":"Nebivolol, an antihypertensive agent, has new application in inhibiting melanoma","volume":"35","author":"Yang","year":"2024","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.bcp.2026.117867_b0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.104149","article-title":"Beta-blockers disrupt mitochondrial bioenergetics and increase radiotherapy efficacy independently of beta-adrenergic receptors in medulloblastoma","volume":"82","author":"Rossi","year":"2022","journal-title":"EBioMedicine"},{"issue":"6","key":"10.1016\/j.bcp.2026.117867_b0175","doi-asserted-by":"crossref","first-page":"5894","DOI":"10.3390\/ijms24065894","article-title":"Blockade of \u00df-adrenergic receptors by nebivolol enables tumor control potential for uveal melanoma in 3D tumor spheroids and 2D cultures","volume":"24","author":"Farhoumand","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"8","key":"10.1016\/j.bcp.2026.117867_b0180","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0071980","article-title":"The \u03b2-blocker nebivolol is a GRK\/\u03b2-arrestin biased agonist","volume":"8","author":"Erickson","year":"2013","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.bcp.2026.117867_b0185","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.molcel.2019.03.031","article-title":"ER and nutrient stress promote assembly of respiratory chain supercomplexes through the PERK-eIF2\u03b1 axis","volume":"74","author":"Balsa","year":"2019","journal-title":"Mol. Cell"},{"key":"10.1016\/j.bcp.2026.117867_b0190","doi-asserted-by":"crossref","unstructured":"X. Wang, Y. Zhang, L. Du, Z. Jiang, Y. Guo, K. Wang, et al., TUDCA alleviates atherosclerosis by inhibiting AIM2 inflammasome and enhancing cholesterol efflux capacity in macrophage, iScience 27(6) (2024) 109849.","DOI":"10.1016\/j.isci.2024.109849"},{"issue":"5","key":"10.1016\/j.bcp.2026.117867_b0195","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.cell.2009.11.007","article-title":"Epithelial-mesenchymal transitions in development and disease","volume":"139","author":"Thiery","year":"2009","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.bcp.2026.117867_b0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.mocell.2024.100176","article-title":"eIF2\u03b1 phosphorylation-ATF4 axis-mediated transcriptional reprogramming mitigates mitochondrial impairment during ER stress","volume":"48","author":"Le","year":"2025","journal-title":"Mol. Cells"},{"issue":"24","key":"10.1016\/j.bcp.2026.117867_b0205","doi-asserted-by":"crossref","first-page":"5507","DOI":"10.1111\/bph.12704","article-title":"Movers and shakers: cell cytoskeleton in cancer metastasis","volume":"171","author":"Fife","year":"2014","journal-title":"Br. J. Pharmacol."},{"issue":"9","key":"10.1016\/j.bcp.2026.117867_b0210","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1111\/bcp.14030","article-title":"Prognostic significance of \u03b1- and \u03b22-adrenoceptor gene expression in breast cancer patients","volume":"85","author":"Rivero","year":"2019","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"2","key":"10.1016\/j.bcp.2026.117867_b0215","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/nrc2069","article-title":"G-protein-coupled receptors and cancer","volume":"7","author":"Dorsam","year":"2007","journal-title":"Nat. Rev. Cancer"},{"issue":"1","key":"10.1016\/j.bcp.2026.117867_b0220","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrd3320","article-title":"G protein-coupled receptors: novel targets for drug discovery in cancer","volume":"10","author":"Lappano","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"issue":"8","key":"10.1016\/j.bcp.2026.117867_b0225","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/nrc2694","article-title":"Signal integration by JNK and p38 MAPK pathways in cancer development","volume":"9","author":"Wagner","year":"2009","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bcp.2026.117867_b0230","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2019.104587","article-title":"\u03b2-blockers: their new life from hypertension to cancer and migraine","volume":"151","author":"Fumagalli","year":"2020","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.bcp.2026.117867_b0235","article-title":"Repurposing of drugs approved for cardiovascular diseases: opportunity or mirage?","volume":"177","author":"Gelosa","year":"2020","journal-title":"Biochem. Pharmacol."},{"issue":"9","key":"10.1016\/j.bcp.2026.117867_b0240","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1038\/s41388-021-02170-0","article-title":"Blockade of beta-adrenergic receptors reduces cancer growth and enhances the response to anti-CTLA4 therapy by modulating the tumor microenvironment","volume":"41","author":"Fj\u00e6stad","year":"2022","journal-title":"Oncogene"},{"issue":"26","key":"10.1016\/j.bcp.2026.117867_b0245","doi-asserted-by":"crossref","first-page":"3777","DOI":"10.1038\/sj.onc.1210172","article-title":"A chemical biology approach identifies a beta-2 adrenergic receptor agonist that causes human tumor regression by blocking the Raf-1\/Mek-1\/Erk1\/2 pathway","volume":"26","author":"Carie","year":"2007","journal-title":"Oncogene"},{"issue":"7","key":"10.1016\/j.bcp.2026.117867_b0250","doi-asserted-by":"crossref","first-page":"3646","DOI":"10.1016\/j.apsb.2025.04.030","article-title":"Discovery of Yersinia LcrV as a novel biased agonist of formyl peptide receptor 1 to bi-directionally modulate intracellular kinases in triple-negative breast cancer","volume":"15","author":"Ge","year":"2025","journal-title":"Acta Pharm. Sin. B"},{"issue":"37","key":"10.1016\/j.bcp.2026.117867_b0255","doi-asserted-by":"crossref","first-page":"23096","DOI":"10.1073\/pnas.2009786117","article-title":"Analysis of beta(2)AR-G(s) and beta(2)AR-G(i) complex formation by NMR spectroscopy","volume":"117","author":"Ma","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"1","key":"10.1016\/j.bcp.2026.117867_b0260","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s43018-024-00893-z","article-title":"Resistance mechanisms and therapeutic strategies of CDK4 and CDK6 kinase targeting in cancer","volume":"6","author":"Asciolla","year":"2025","journal-title":"Nat Cancer"},{"issue":"7","key":"10.1016\/j.bcp.2026.117867_b0265","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/s41571-020-0341-y","article-title":"Targeting apoptosis in cancer therapy","volume":"17","author":"Carneiro","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"16","key":"10.1016\/j.bcp.2026.117867_b0270","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","article-title":"Sacituzumab govitecan in metastatic triple-negative breast cancer","volume":"384","author":"Bardia","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcp.2026.117867_b0275","article-title":"PRMT1-mediated PARP1 methylation drives lung metastasis and chemoresistance via P65 activation in triple-negative breast cancer","volume":"8","author":"Zhang","year":"2025","journal-title":"Research (Wash D C)"},{"issue":"8039","key":"10.1016\/j.bcp.2026.117867_b0280","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1038\/s41586-024-08031-6","article-title":"AKT and EZH2 inhibitors kill TNBCs by hijacking mechanisms of involution","volume":"635","author":"Schade","year":"2024","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.bcp.2026.117867_b0285","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/s41392-025-02169-z","article-title":"A first-in-class selective inhibitor of ERK1\/2 and ERK5 overcomes drug resistance with a single-molecule strategy","volume":"10","author":"Xiao","year":"2025","journal-title":"Signal Transduct. Target. Ther."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295226001991?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295226001991?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T09:32:17Z","timestamp":1777455137000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295226001991"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":57,"alternative-id":["S0006295226001991"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2026.117867","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nebivolol-induced bi-directional modulation of intracellular kinases contributes to the inhibition of triple-negative breast cancer","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2026.117867","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117867"}}